Decision and Details
Board of DirectorsExecution of a syndicated loan agreement
To finance the planned construction of the Second Formulation Building (tentative name), which will house a new production line for powdered dialysis agents and consolidate the functions relocated from the Daito Plant. After considering capital efficiency and financial soundness, the company decided to raise the funds through a syndicated loan.
The execution of this agreement is expected to have a minor impact on results for the fiscal year ending March 2026.
| Item | Details |
|---|---|
| Matter Covered | Execution of a syndicated loan agreement |
| Decision-Making Body | Board of Directors |
| Decision Date | 31 March 2026 |
| Implementation Date | 31 March 2026 (agreement execution date, completed) / 30 September 2026 to 15 February 2029 (commitment period, scheduled and applicable period) |
| Period Covered | 30 September 2026 to 15 February 2029 (commitment period) |
| Amount | Arranged amount: ¥13.4 billion |
| Quantity / scale | Participating financial institutions: 8 banks |
| Impact on Business Performance | The execution of this agreement is expected to have a minor impact on results for the fiscal year ending March 2026. |
| Reason | To finance the planned construction of the Second Formulation Building (tentative name), which will house a new production line for powdered dialysis agents and consolidate the functions relocated from the Daito Plant. After considering capital efficiency and financial soundness, the company decided to raise the funds through a syndicated loan. |
| Future plans | The commitment period will run from 30 September 2026 to 15 February 2029. Going forward, the company will continue working toward sustainable growth and further enhancement of corporate value in close cooperation with each financial institution. |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To finance the construction of the Second Formulation Building (tentative name), which will house a new production line for powdered dialysis agents and consolidate the functions relocated from the Daito Plant. After considering capital efficiency and financial soundness, the company decided to raise the funds through a syndicated loan.